Relative Value

There is not enough data to reliably calculate the relative value of IVX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IVX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
24
Median 3Y
6.7
Median 5Y
13.3
Industry
2.6
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-25.7
Industry
21.4
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-9.5
Industry
16.4
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
22.8
vs History
90
vs Industry
71
Median 3Y
1.4
Median 5Y
2.3
Industry
2.2
vs History
vs Industry
25
Median 3Y
6.2
Median 5Y
12.8
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-6
Median 5Y
-24.4
Industry
13
vs History
vs Industry
Median 3Y
-6
Median 5Y
-24.4
Industry
16.5
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-8.8
Industry
15.6
vs History
vs Industry
Median 3Y
-5
Median 5Y
-5
Industry
18.7
vs History
90
vs Industry
72
Median 3Y
1.5
Median 5Y
2.4
Industry
1.9

Multiples Across Competitors

IVX Competitors Multiples
Invion Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Invion Ltd
ASX:IVX
7.7m AUD 0 -0.9 -0.8 -0.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.9 38.1 40.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.3B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.3B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
220.6B GBP 5.1 31.6 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
270.1B USD 4.2 14.2 10.1 11.9
CH
Novartis AG
SIX:NOVN
218B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/S Multiple
Revenue Growth P/S to Growth
AU
Invion Ltd
ASX:IVX
Average P/S: 72
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
17.6
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.4
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.4
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
5.1
8%
0.6
US
Merck & Co Inc
NYSE:MRK
4.2
4%
1.1
CH
Novartis AG
SIX:NOVN
4.9
5%
1
DK
Novo Nordisk A/S
CSE:NOVO B
5.2
5%
1
IE
E
Endo International PLC
LSE:0Y5F
92.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
AU
Invion Ltd
ASX:IVX
Average P/E: 25.1
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.9
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBITDA: 440.1
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBIT: 1 883.7
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5